Tevogen Bio Shareholders Approve Reverse Split Authorization

Tevogen Bio Holdings ( (TVGN) ) has shared an announcement.

On February 19, 2026, Tevogen Bio Holdings Inc. held a special meeting of stockholders at which investors voted on amending the company’s 2024 equity incentive plan and authorizing a reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board’s discretion. Both proposals received strong support, with the plan amendment and the reverse stock split authorization each approved by substantial majorities of the shares present, positioning the company to adjust its capital structure and equity incentives in line with future strategic needs.

The most recent analyst rating on (TVGN) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Tevogen Bio Holdings stock, see the TVGN Stock Forecast page.

Spark’s Take on TVGN Stock

According to Spark, TipRanks’ AI Analyst, TVGN is a Neutral.

The score is driven primarily by very weak financial performance (no revenue, ongoing losses, negative free cash flow, and negative equity), which outweighs the benefit of lower debt. Technicals add further pressure with a strong downtrend and negative MACD, while valuation metrics offer limited support due to a negative P/E and no dividend yield.

To see Spark’s full report on TVGN stock, click here.

More about Tevogen Bio Holdings

Tevogen Bio Holdings Inc. operates in the biopharmaceutical sector, focusing on developing and commercializing medical therapies and related technologies. As a publicly traded company, it relies on stockholder approvals for key governance, capital structure, and incentive compensation decisions that support its strategic and operational initiatives.

Average Trading Volume: 912,305

Technical Sentiment Signal: Sell

Current Market Cap: $55.92M

See more data about TVGN stock on TipRanks’ Stock Analysis page.